title: Do we need three players in COPD treatment?
authors.affiliation: Department of Cardiologic, Thoracic and Vascular Sciences, University of Padua, Padua, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Maestrelli
authors.forename: P
authors.initials: P
authors.lastname: Mason
authors.forename: F
authors.initials: F
authors.lastname: Costa
authors.forename: P
authors.initials: P
authors.lastname: Paggiaro
mesh_terms: D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000730:Androstadienes / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D005260:Female; D000068298:Fluticasone; D006801:Humans; D008297:Male; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D000068299:Salmeterol Xinafoate; D012602:Scopolamine Derivatives / Q000627:therapeutic use*; D000069447:Tiotropium Bromide
chemical_list: D000730:Androstadienes; D001993:Bronchodilator Agents; D012602:Scopolamine Derivatives; D000068299:Salmeterol Xinafoate; D000068298:Fluticasone; D000420:Albuterol; D000069447:Tiotropium Bromide